

April 09, 2019

To,

General Manager, Department of Corporate Services, 14 <sup>th</sup> Floor, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001	National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051.	Mr. Vinod Goel Group CFO, Company Secretary & Compliance Officer, Panacea Biotec Limited Ambala Chandigarh Highway, Lalru, Punjab 140501
--	---	---

## DISCLOSURE UNDER REGULATION 29(1) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

### Part-A- Details of the Acquisition

1. Name of the Target Company (TC)	Panacea Biotec Limited		
2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Vistra ITCL (India) Limited ('Vistra ITCL') (In our capacity as Debenture Trustee) The IL&FS Financial Centre, Plot C-22, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051		
3. Whether the acquirer belongs to Promoter/Promoter group	No		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)		
5. Details of the acquisition as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable (*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	----	----	----
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	----	----	----
c) Voting rights (VR) otherwise than by equity shares	----	----	----
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	----	----	----



Page 1 of 3

<b>Total (a+b+c+d)</b>			
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired	----	----	----
b) VRs acquired/sold otherwise than by equity shares	----	----	----
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	----	----	----
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	1,52,56,512	24.91%	----
<b>Total (a+b+c+d)</b>	<b>1,52,56,512</b>	<b>24.91%</b>	<b>----</b>
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	----	----	----
b) VRs otherwise than by equity shares	----	----	----
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	----	----	----
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	1,52,56,512	24.91%	----
<b>Total (a+b+c+d)</b>	<b>1,52,56,512</b>	<b>24.91%</b>	<b>----</b>
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Pledge of equity shares		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	-----		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	April 05, 2019.		
Equity share capital / total voting capital of the TC before the said acquisition	6,12,50,746 Shares (As per BSE shareholding pattern as on December 2018)		
Equity share capital/ total voting capital of the TC after the said acquisition	6,12,50,746 Shares (As per BSE shareholding pattern as on December 2018)		
Total diluted share/voting capital of the TC after the said acquisition	-----		



**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.


(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated

1,52,56,512 (27,82,299 + 8,16,500 + 8,97,000 + 9,68,500 + 2,99,500 +25,11,000 + 41,05,000 + 10,80,700 + 11,71,013 + 3,07,000 + 3,18,000) equity shares of Panacea Biotec Limited have been pledged with Vistra ITCL (India) Limited on April 05, 2019 in capacity as a Debenture Trustee to secure the issue of Non-Convertible Debentures (NCDs) issued by Panacea Biotec Limited.

As per the Securities Exchange Board of India letter dated August 08, 2014 (enclosed for your reference), the primary onus of complying with the provisions of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is of the lender, debenture holder and not on the Trustee. However, out of abundant caution, Vistra ITCL in its capacity as security trustee and debenture trustee is disclosing and filing this disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

For Vistra ITCL (India) Limited

  
Jatin Chonani  
Compliance Officer



Place: Mumbai

Encl.: As above